Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours

R. Luksch, G. Grignani, F. Fagioli, A. Brach del Prever, M. Podda, S. Aliberti, M. Casanova, A. Prete, G. Hanau, A. Tamburini, P. Allione, A. Tienghi, S. Ferrari, P. Collini, A. Marchianò, L. Gandola, M. Aglietta, E. Madon, P. Picci, F. Fossati-Bellani

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of the study was to determine the activity and toxicity of melphalan as a single agent given in up-front therapy for patients with newly-diagnosed Ewing's family tumours with bone/bone marrow metastases. Nineteen patients were enrolled from 2001 to 2004. The treatment consisted of up-front therapy with melphalan (two courses of 50 mg/m2, 3 weeks apart). The overall rate of response to melphalan (complete response + partial response, according to the RECIST criteria) was 78%. Transient grade 3-4 neutropenia, thrombocytopenia and anaemia were recorded in 97%, 81% and 28% of melphalan courses, respectively. No other relevant toxicities were recorded. Melphalan proved to be active in up-front treatment at non-myeloablative doses, and its toxicity was predictable and manageable. The schedule adopted did not interfere with any further intensive chemotherapy or myeloablative treatment in the majority of cases.

Original languageEnglish
Pages (from-to)885-890
Number of pages6
JournalEuropean Journal of Cancer
Volume43
Issue number5
DOIs
Publication statusPublished - Mar 2007

Keywords

  • Ewing's family tumours
  • Melphalan
  • Metastatic

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours'. Together they form a unique fingerprint.

Cite this